Effect of angiotensin II receptor blocker on glucose-induced mRNA expressions of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rat mesangial cells

Chinese Medical Journal

Volumn 120, Issue 21, 2007, Pages 1886-1889

  Ding, He Lin ^a   Guo, Ying ^a   Xu, Ming Tong ^a   Li, Hai Yan ^a   Fu, Zu Zhi ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Angiotensin II; High glucose; Matrix metalloproteinase 9; Tissue inhibitor of metalloproteinase 1

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; GELATINASE B; GLUCOSE; MESSENGER RNA; SARALASIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; GENE EXPRESSION REGULATION; INCUBATION TIME; MESANGIUM CELL; NONHUMAN; PROTEIN DEGRADATION; RADIOIMMUNOASSAY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT;

EID: 36248931080     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200711010-00006     Document Type: Article

References (21)

1. Zhang Y, Chen B, Hou XH, Guan GJ, Liu G, Liu HY, et al. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats. Chin Med J 2007; 120: 988-995.
2. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-868.
3. Dong FQ, Li H, Cai WM, Tho J, Li Q, Ruan Y, et al. Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats. Chin Med J 2004; 117: 140-1044.
4. McLennan SV, Wang XY, Moreno V, Yue DK, Twigg SM. Connective tissue growih factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology 2004; 145: 5646-5655.
5. McLennan SV, Martell SK, Yue DK. Effects of mesangium glycation on matrix metnlloproteinase activities: possible role in diabetic nephropathy. Diabetes 2002; 51: 2612-2618.
6. Umezono T, Toyoda M, Kato M, Miyauchi M, Kimura M, Mazuyama M, et al. Glomerular expression of CTGF, TGF-beta 1 and type IV collagen in diabetic nephropathy. J Nepbrol 2006; 19: 751-757.
7. Pedchenko VY, Chetyrkin SV, Chuang P, Ham AJ, Saleem MA, Mathieson PW, et al. Mechanism of perturbation of integrin-mediated cell-matrix interactions by reactive carbonyl compounds and its implication fior pathogenesis of diabetic nephropathy. Diabetes 2005; 54: 2952-2960.
8. Sun SZ, Wang Y, Li Q, Tian YJ, Liu MH, Yu YH. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats. Chin Med J 2006; 119: 814-821.
9. Odaka C, Tanioka M, Itoh T. Matrix metalloproteipase-9 in macrophages induces thymic neovascularization following thymocyte apoptosis. J Immunol 2005; 174: 846-853.
10. Kugler A. Matrix metalloproteinases and their inhibitors. Anticancer Res 1999; 1589-1592.
11. Wahab NA, Harpe K, Masori RM. Expression of extracellular matrix molecules in human mesangial cells in response to prolonged hyperglycemia. Biochem J 1996; 316 (Pt 3): 985-992.
12. Mclennan SV, Kelly DJ, Cox AJ, Cao Z, Lyons JG, Yue DK, et al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibitions on the expression and activities of matrix metalloproteinase. Diabetologia 2002; 45: 268-275.
13. Lupia E, Elliot SJ, Lenz O, Zheng F, Hattori M, Striker GE, et al. IGF-1 decreases tollagen degradation in diabetic NOD mesangial cells implications for diabetic nephropathy. Diabetes 1999; 48: 1639-164
14. Wahab NB, Mason RM. Modulation of neutral protease. expression in human mesangial cells by hyperglycaemic. culture. Biochem J 1996; 320 (Pt 3): 777-783.
15. Van Huyen JP, Viltard M, Nehiri T, Freund N, Bélair W, Martinerie C, et al. Expression of matrix metalloproteinases MMP-2 artd MMP-9 is altered during nephrogenesis in fetuses from diabetic rats. Lab Invest 2007; 87: 680-689.
16. Yano N, Suzuki D, Endoh NE, Zhao TC, Padbury JF, Tseng YT. A novel phosphoinositide 3-idnase-dependent pathway for angiotensin II/AT- 1 receptor-mediated induction of collagen synthesis in MES-13 mesangial gells. J Biol Chem 2007; 282: l8819-18830.
17. Westermann D, Rutschow S, Jäger S, Binderer A, Anker S, Riad A, el at. Contributions inflammation and cardiac matrix metilloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role, of angiotensin type 1. receptor antagonism. Diabetes 2007; 56: 641-646.
18. Yano N, Suzuki D, Endoh M, Zhao TC, Padbury JF, Tseng VT. A novel phosphoinositide 3-kinase-dependent pathway for Angiotensin II/AT-1 receptor-mediated induction of collagen synthesis in MES-13 mesangial cells. J Bioi Chem 20-67; 282: 18819-18830.
19. Liu BC, Xu Y, Ma KL, Huang HQ, Yin LF, Liu DG. Effects of irbesartan on the expression of matrix metalloproteinase-2/tissue inhibitor of - metalloproteinase-2 in streptozotocin-induced diabetic rat kidney. Chin Med J 2005; 118: 1040-1044.
20. Singh R, Alavi,N, Singh AK, Leehey DJ. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 1999; 48: 2066-2013.
21. McLennan SV, Kelly W, Cox AJ, Cao Z, Lyons JG, Nue DK, et al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 2002; 45: 268-275.